Literature DB >> 11828282

Predictors of outcome after the Fontan operation: is hypoplastic left heart syndrome still a risk factor?

J William Gaynor1, Nancy D Bridges, Mitchell I Cohen, William T Mahle, William M Decampli, James M Steven, Susan C Nicolson, Thomas L Spray.   

Abstract

OBJECTIVE: This study was undertaken to evaluate factors contributing to a decrease in early mortality and morbidity after the Fontan procedure between January 1, 1992, and December 31, 1999.
METHODS: Outcomes evaluated were early survival, duration of pleural effusions, and duration of hospitalization. Potential predictors evaluated included anatomic diagnosis, presence of a common atrioventricular valve, preoperative pulmonary artery pressure, type of Fontan operation, type of intentional right-to-left shunt or baffle fenestration, and use of modified ultrafiltration.
RESULTS: The modified Fontan procedure was performed in 332 patients at a median age of 22 months (range, 11-380 months) and a median weight of 11 kg (range, 5.8-120 kg). Prior stage I reconstructive surgery for classic or variant hypoplastic left heart syndrome had been performed in 205 (53%) of 332 patients, and 318 (96%) had undergone an interim superior cavopulmonary connection. A lateral-tunnel Fontan operation was performed in 281 patients, and an extracardiac conduit Fontan operation was performed in 51 patients. An intentional right-to-left shunt was created in 298 (90%) patients. Between 1992 and 1999, the outcome after the modified Fontan operation improved significantly. Overall mortality was 6.6% (22/332), with only 2 deaths since 1994. Morbidity was also reduced, with a decreased duration of pleural effusions and decreased hospital stay. In a multivariable analysis of the entire cohort, only the presence of a common atrioventricular valve (odds ratio, 7.64; 95% confidence limits, 2.07-28.14; P =.0002) and increased preoperative pulmonary artery pressure (odds ratio, 1.46/1 mm Hg increase; 95% confidence limits, 1.2-1.78; P <.001) increased the risk of early death, whereas use of a single-punch fenestration in a lateral-tunnel Fontan (odds ratio, 0.06; 95% confidence limits, 0.01-0.65; P =.02) and use of modified ultrafiltration (odds ratio, 0.14; 95% confidence limits, 0.03-0.72; P =.019) decreased the risk of death. The risk of prolonged pleural effusions (>3 days) was increased in patients with hypoplastic left heart syndrome (odds ratio, 1.73; 95% confidence limits, 1.07-2.81; P =.03) and was decreased by use of a single-punch fenestration in a lateral-tunnel Fontan operation (odds ratio, 0.17; 95% confidence limits, 0.07-0.4; P <.001), as well as by the use of modified ultrafiltration (odds ratio, 0.25; 95% confidence limits, 0.15-0.40; P <.01).
CONCLUSIONS: In a contemporary series of Fontan operations performed largely in patients with hypoplastic left heart syndrome or variants, systemic ventricle morphology had no effect on mortality. Some patient characteristics, however, continue to influence outcome. The decrease in mortality and morbidity in the current era is attributed to changes in management strategies, specifically the use of modified ultrafiltration and baffle fenestration.

Entities:  

Mesh:

Year:  2002        PMID: 11828282     DOI: 10.1067/mtc.2002.119337

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  28 in total

1.  Non-invasive assessment of ventricular force-frequency relations in the univentricular circulation by tissue Doppler echocardiography: a novel method of assessing myocardial performance in congenital heart disease.

Authors:  M M H Cheung; J F Smallhorn; B W McCrindle; G S Van Arsdell; A N Redington
Journal:  Heart       Date:  2005-10       Impact factor: 5.994

Review 2.  Long-term results of the Fontan operation.

Authors:  D J Driscoll
Journal:  Pediatr Cardiol       Date:  2007 Nov-Dec       Impact factor: 1.655

3.  Miniaturized biocompatible cardiopulmonary bypass for the Fontan procedure.

Authors:  Keiichi Itatani; Kagami Miyaji; Takashi Miyamoto; Nobuyuki Inoue; Takahiro Tomoyasu; Satoshi Kohira; Hajime Sato; Kuniyoshi Ohara
Journal:  Surg Today       Date:  2010-11-03       Impact factor: 2.549

4.  Early Postoperative Albumin Administration Contributes to Morbidity After the Fontan Operation.

Authors:  Hayden J Zaccagni; Jeffrey A Alten; David C Cleveland; R Tyler Argent; Mark A Law; Ayesha S Bryant; Santiago Borasino
Journal:  Pediatr Cardiol       Date:  2016-06-09       Impact factor: 1.655

Review 5.  Fontan Operation: Indications, Short and Long Term Outcomes.

Authors:  P Syamasundar Rao
Journal:  Indian J Pediatr       Date:  2015-06-20       Impact factor: 1.967

Review 6.  The intensive care of infants with hypoplastic left heart syndrome.

Authors:  U Theilen; L Shekerdemian
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-03       Impact factor: 5.747

7.  Fontan hemodynamics from 100 patient-specific cardiac magnetic resonance studies: a computational fluid dynamics analysis.

Authors:  Christopher M Haggerty; Maria Restrepo; Elaine Tang; Diane A de Zélicourt; Kartik S Sundareswaran; Lucia Mirabella; James Bethel; Kevin K Whitehead; Mark A Fogel; Ajit P Yoganathan
Journal:  J Thorac Cardiovasc Surg       Date:  2013-12-31       Impact factor: 5.209

Review 8.  Management of acute heart failure in adult patients with congenital heart disease.

Authors:  Alexander Van De Bruaene; Lukas Meier; Walter Droogne; Pieter De Meester; Els Troost; Marc Gewillig; Werner Budts
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

9.  Imaging and patient-specific simulations for the Fontan surgery: current methodologies and clinical applications.

Authors:  Diane A de Zélicourt; Alison Marsden; Mark A Fogel; Ajit P Yoganathan
Journal:  Prog Pediatr Cardiol       Date:  2010-12-01

10.  Follow-up study of pulmonary artery configuration in hypoplastic left heart syndrome.

Authors:  Toshihide Nakano; Koji Fukae; Hiromichi Sonoda; Tsuyoshi Tachibana; Masaki Kajimoto; Yusuke Ando; Hideaki Kado
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.